Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):676–680. doi: 10.1097/MPG.0000000000001213

Table 1.

Dietary Intake, Stool Fat Absorption, Plasma Fatty Acids by Placebo and LYM-X-SORB (LXS) at Baseline, 3 and 12 Months

Time Point Effect of treatment
Baseline 3 month 12 month P0-33 P0-3-124
Dietary Fat, g1,5
 Placebo 98 ± 402 102 ± 30 106 ± 32 0.86 0.57
 LXS 97 ± 29 99 ± 34 105 ± 36
Pancreatic Enzymes, Lipase Units1,6
 Placebo 315,938 ± 129,583 327,870 ± 126,817 340,410 ± 123,118 0.80 0.48
 LXS 288,062 ± 123,885 289,709 ± 128,251 264,533 ± 97,713
Coefficient of Fat Absorption, %7
 Placebo 84 ± 12 85 ± 19 88 ± 11 0.16 0.34
 LXS 82 ± 11 88 ± 7** 87 ± 8**
Lauric (C12:0), nmol/L1,8
 Placebo 23 ± 15 21 ± 12 24 ± 19 0.035 0.039
 LXS 19 ± 12 34 ± 55* 22 ± 23
Palmitoleic (C16:1ω7), nmol/L8
 Placebo 243 ± 154 221 ± 101 236 ± 116 0.003 0.009
 LXS 214 ± 105 299 ± 186*** 292 ± 173**
Linoleic Acid (C18:2ω6), nmol/L8
 Placebo 2333 ± 491 2380 ± 552 2358 ± 500 0.069 0.15
 LXS 2230 ± 528 2522 ± 754** 2405 ± 571*
Oleic (C18:1ω9), nmol/L1,8
 Placebo 1872 ± 557 1798 ± 488 1839 ± 490 0.017 0.046
 LXS 1762 ± 367 2068 ± 775** 1997 ± 589*
Arachidonic (C20:4ω6), nmol/L8
 Placebo 454 ± 143 432 ± 129 458 ± 138 0.023 0.047
 LXS 430 ± 127 463 ± 161 460 ± 143**
Docosatetranoic (C22:4ω6), nmol/L1,8
 Placebo 25 ± 9 23 ± 8 23 ± 8 0.012 0.037
 LXS 22 ± 7 28 ± 13** 26 ± 11**
Total Fatty Acids, mmol/L1,8
 Placebo 9.16 ± 2.18 9.12 ± 2.26 9.30 ± 2.00 0.015 0.046
 LXS 8.56 ± 1.64 10.14 ± 3.63** 9.70 ± 2.83**
1

Log transformation was applied for skewed variables in the mixed models.

2

Mean ± SD (all such values).

3

P0-3 is testing for partial randomization group × time interaction between baseline and 3 month from a mixed effects linear regression model that included baseline, 3, and 12 months data (i. randomization group × time interaction was used).

4

P0-3-12 is testing for randomization group × time interaction between baseline and 3, and 12 month.

5

n=54, 37, and 35 for Placebo group, and n=44, 31, and 23 for LXS group at baseline, 3, and 12 months, respectively.

6

n=56, 46, and 39 for Placebo group, and n=54, 40, and 30 for LXS group at baseline, 3, and 12 months, respectively.

7

n=41, 36, and 30 for Placebo group, and n=35, 27, and 20 for LXS group at baseline, 3, and 12 months, respectively.

8

n=56, 46, and 39 for Placebo group, and n=51, 40, and 31 for LXS group at baseline, 3, and 12 months, respectively.

*(P<0.05) **(P<0.01) ***(P<0.001) difference from baseline within randomization group.